Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice

Journal of Immunology

Volumn 183, Issue 1, 2009, Pages 604-612

  Percopo, Caroline M ^a   Qiu, Zhijun ^a   Phipps, Simon ^b   Foster, Paul S ^b   Domachowske, Joseph B ^c   Rosenberg, Helene F ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; VIRUS ANTIGEN; FIXATIVE; FORMALDEHYDE; INACTIVATED VACCINE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EOSINOPHIL; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATION; LUNG; LUNG FLUID; LUNG LAVAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTECTION; PROTEIN BLOOD LEVEL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINATION; VIRUS NEUTRALIZATION; VIRUS PNEUMONIA; VIRUS TITRATION; WEIGHT REDUCTION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MOUSE MUTANT; MURINE PNEUMONIA VIRUS; PATHOLOGY; VIROLOGY; VIRUS INFECTION;

ANIMALS; ANTIGENS, VIRAL; CELL LINE; EOSINOPHILS; FIXATIVES; FORMALDEHYDE; HYPERSENSITIVITY; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MURINE PNEUMONIA VIRUS; PNEUMOVIRUS INFECTIONS; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 68949110128     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802270     Document Type: Article

References (67)

1. Karron, R. A., P. F. Wright, R. B. Belshe, B. Thumar, R. Casey, F. Newman, F. P. Polack, V. B. Randolph, A. Deatly, J. Hackell, et al. 2005. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191: 1093-1104.
2. Belshe, R. B., F. K. Newman, E. L. Anderson, P. F. Wright, R. A. Karron, S. Tollefson, F. W. Henderson, H. C. Meissner, S. Madhi, D. Roberton, et al. 2004. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J. Infect. Dis. 190: 2096-2103.
3. Domachowske, J. B., C. A. Bonville, and H. F. Rosenberg. 2004. Animal models for studying respiratory syncytial virus infection and its long term effects on lung function. Pediatr. Infect. Dis. J. 23(Suppl. 11): S228-S234.
4. Easton, A. J., J. B. Domachowske, and H. F. Rosenberg. 2004. Animal pneumoviruses: molecular genetics and pathogenesis. Clin. Microbiol. Rev. 17: 390-412.
5. Gershwin, L. J. 2007. Bovine respiratory syncytial virus infection: immunopathogenic mechanisms. Anim. Health Res. Rev. 8: 207-213.
6. Valarcher, J. F., and G. Taylor. 2007. Bovine respiratory syncytial virus infection. Vet. Res. 38: 153-180.
7. Meyer, G., M. Deplanche, and F. Schelcher. 2008. Human and bovine respiratory syncytial virus vaccine research and development. Comp. Immunol. Microbiol. Infect. Dis. 31: 191-225.
8. Rosenberg, H. F., and J. B. Domachowske. 2008. Pneumonia virus of mice: severe respiratory infection in a natural host. Immunol. Lett. 118: 6-12.
9. Easton, A. J., J. B. Domachowske, and H. F. Rosenberg. 2006. Pneumonia virus of mice. In Perspectives in Medical Virology, Vol. 12. P. Cane P, ed. Elsevier, Amsterdam, pp. 299-319.
10. Ellis, J. A., B. V. Martin, C. Waldner, K. D. Dyer, J. B. Domachowske, and H. F. Rosenberg. 2007. Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-γ receptor deficient mice. Vaccine 25: 1085-1095.
11. Dibben, O., L. C. Thorpe, and A. J. Easton. 2008. Roles of the PVM M2-1, M2-2 and P gene ORF 2 (P-2) proteins in viral replication. Virus Res. 131: 47-53.
12. Krempl, C. D., A. Wnekowicz, E. W. Lamirande, G. Nayebagha, P. L. Collins, and U. J. Buchholz. 2007. Identification of a novel virulence factor in recombinant pneumonia virus of mice. J. Virol. 81: 9490-9501.
13. Castilow, E. M., M. R. Olson, and S. M. Varga. 2007. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol. Res. 39: 225-239.
14. Openshaw, P. J., and J. S. Tregoning. 2005. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin. Microbiol. Rev. 18: 541-555.
15. Connors, M., N. A. Giese, A. B. Kulkarni, C. Y. Firestone, H. C. Morse 3rd, and B. R. Murphy. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68: 5321-5325.
16. Waris, M. E., C. Tsou, D. D. Erdman, S. R. Zaki, and L. J. Anderson. 1996. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70: 2852-2860.
17. Castilow, E. M., D. K. Meyerholz, and S. M. Varga. 2008. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 180: 2376-2384.
18. Polack, F. P., M. N. Teng, P. L. Collins, G. A. Prince, M. Exner, H. Regele, D. D. Lirman, R. Rabold, S. J. Hoffman, C. L. Karp, et al. 2002. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196: 859-865.
19. Moghaddam, A., W. Olszewska, B. Wang, J. S. Tregoning, R. Helson, Q. J. Sattentau, and P. J. Openshaw. 2006. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat. Med. 12: 905-907.
20. Delgado, M. F., S. Coviello, A. C. Monsalvo, G. A. Melendi, J. Z. Hernandez, J. P. Batalle, L. Diaz, A. Trento, H. Y. Chang, W. Mitzner, et al. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15: 34-41.
21. Kalina, W. V., A. R. Woolums, R. D. Berghaus, and L. J. Gershwin. 2004. Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle. Vaccine 22: 1465-1474.
22. Antonis, A. F., R. S. Schrijver, F. Daus, P. J. Steverink, N. Stockhofe, E. J. Hensen, J. P. Langedijk, and R. G. van der Most. 2003. Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis. J. Virol. 77: 12067-12073.
23. Polack, F. P., P. G. Auwaerter, S. H. Lee, H. C. Nousari, A. Valsamakis, K. M. Leiferman, A. Diwan, R. J. Adams, and D. E. Griffin. 1999. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 5: 629-634.
24. de Swart, R. L., B. G. van den Hoogen, T. Kuiken, S. Herfst, G. van Amerongen, S. Yüksel, L. Sprong, and A. D. Osterhaus. 2007. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine 25: 8518-8528.
25. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89: 422-434.
26. Yu, C., A. B. Cantor, H. Yang, C. Browne, R. A. Wells, Y. Fujiwara, and S. H. Orkin. 2002. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J. Exp. Med. 195: 1387-1395.
27. Lee, J. J., D. Dimina, M. P. Macias, S. I. Ochkur, M. P. McGarry, K. R. O'Neill, C. Protheroe, R. Pero, T. Nguyen, S. A. Cormier, et al. 2004. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305: 1773-1776.
28. Castilow, E. M., M. R. Olson, and S. M. Varga. 2007. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol. Res. 39: 225-239.
29. Rosenberg, H. F., and J. B. Domachowske. 2009. Respiratory viruses and eosinophils: exploring the connections. Antiviral Res. In press.
30. Phipps, S., C. E. Lam, S. Mahalingam, M. Newhouse, R. Ramirez, H. F. Rosenberg, P. S. Foster, and K. I. Matthaei. 2007. Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood 110: 1578-1586.
31. Rosenberg, H. F., and J. B. Domachowske. 2008. Pneumonia virus of mice: severe respiratory infection in a natural host. Immunol. Lett. 118: 6-12.
32. West, K., L. Petrie, D. M. Haines, C. Konoby, E. G. Clark, K. Martin, and J. A. Ellis. 1999. The effect of formalin-inactivated vaccine on respiratory disease associated with bovine respiratory syncytial virus infection in calves. Vaccine 17: 809-820.
33. Prince, G. A., S. J. Curtis, K. C. Yim, and D. D. Porter. 2001. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 82: 2881-2888.
34. Dyer, K. D., I. M. Schellens, C. A. Bonville, B. V. Martin, J. B. Domachowske, and H. F. Rosenberg. 2007. Efficient replication of pneumonia virus of mice (PVM) in a mouse macrophage cell line. Virol. J. 4: 48.
35. Domachowske, J. B., C. A. Bonville, J. L. Gao, P. M. Murphy, A. J. Easton, and H. F. Rosenberg. 2000. The chemokine macrophage-inflammatory protein-1α and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection. J. Immunol. 165: 2677-2682.
36. Domachowske, J. B., C. A. Bonville, K. D. Dyer, A. J. Easton, and H. F. Rosenberg. 2000. Pulmonary eosinophilia and production of MIP-1α are prominent responses to infection with pneumonia virus of mice. Cell. Immunol. 200: 98-104.
37. Johnson, T. R., and B. S. Graham. 1999. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J. Virol. 73: 8485-8495.
38. Bonville, C. A., N. J. Bennett, M. Koehnlein, D. M. Haines, J. A. Ellis, A. M. DelVecchio, H. F. Rosenberg, and J. B. Domachowske. 2006. Respiratory dysfunction and proinflammatory chemokines in the pneumonia virus of mice (PVM) model of viral bronchiolitis. Virology 349: 87-95.
39. Harrison, A. M., C. A. Bonville, H. F. Rosenberg, and J. B. Domachowske. 1999. Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am. J. Respir. Crit. Care Med. 159: 1918-1924.
40. Garofalo, R. P., J. Patti, K. A. Hintz, V. Hill, P. L. Ogra, and R. C. Welliver. 2001. Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J. Infect. Dis. 184: 393-399.
41. Domachowske, J. B., K. D. Dyer, C. A. Bonville, and H. F. Rosenberg. 1998. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J. Infect. Dis. 177: 1458-1464.
42. Rosenberg, H. F., and J. B. Domachowske. 2001. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. J. Leukocyte Biol. 70: 691-698.
43. Humbles, A. A., C. M. Lloyd, S. J. McMillan, D. S. Friend, G. Xanthou, E. E. McKenna, S. Ghiran, N. P. Gerard, C. Yu, S. H. Orkin, and C. Gerard. 2004. A critical role for eosinophils in allergic airways remodeling. Science 305: 1776-1779.
44. Swartz, J. M., K. D. Dyer, A. W. Cheever, T. Ramalingam, L. Pesnicak, J. B. Domachowske, J. J. Lee, N. A. Lee, P. S. Foster, T. A. Wynn, and H. F. Rosenberg. 2006. Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood 108: 2420-2427.
45. Jacobsen, E. A., S. I. Ochkur, R. S. Pero, A. G. Taranova, C. A. Protheroe, D. C. Colbert, N. A. Lee, and J. J. Lee. 2008. Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells. J. Exp. Med. 205: 699-710.
46. Hogan, S. P. 2007. Recent advances in eosinophil biology. Int. Arch. Allergy Immunol. 143(Suppl. 1): 3-14.
47. Bonjardim, C. A., P. C. P. Ferreira, and E. G. Kroon. 2009. Interferons: signaling, antiviral and viral evasion. Immunol. Lett. 122: 1-11.
48. Bonville, C. A., C. M. Percopo, K. D. Dyer, J. Gao, C. Prussin, B. Foster, H. F. Rosenberg, and J. B. Domachowske. 2009. Interferon- γcoordinates CCL3-mediated neutrophil recruitment in vivo. BMC Immunol. 10: 14.
49. Tebbey, P. W., M. Hagen, and G. E. Hancock. 1988. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188: 1967-1972.
50. Johnson, T. R., J. E. Johnson, S. R. Roberts, G. W. Wertz, R. A. Parker, and B. S. Graham. 1998. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol. 72: 2871-2880.
51. Sparer, T. E., S. Matthews, T. Hussell, A. J. Rae, B. Garcia-Barreno, J. A. Melero, and P. J. Openshaw. 1998. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187: 1921-1926.
52. Johnson, T. R., and B. S. Graham. 2004. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 23: S46-S57.
53. + T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J. Virol. 78: 8753-8760.
54. Johnson, T. R., M. N. Teng, P. L. Collins, and B. S. Graham. 2004. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J. Virol. 78: 6024-6032. (Pubitemid 38661690)
55. Piedra, P. A., P. R. Wyde, W. L. Castleman, M. W. Ambrose, A. M. Jewell, D. J. Speelman, and S. W. Hildreth. 1993. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. Vaccine 11: 1415-1423.
56. Boelen, A., A. Andeweg, J. Kwakkel, W. Lokhorst, T. Bestebroer, J. Dormans, and T. Kimman. 2000. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 19: 982-991.
57. 2 muscarinic receptor dysfunction, and antiviral effects. J. Exp. Med. 190: 1465-1478.
58. + T cells. J. Allergy Clin. Immunol. 122: 69-77.
59. Castilow, E. M., K. L. Legge, and S. M. Varga. 2008. Cutting edge: eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 181: 6692-6696.
60. Dyer, K. D., J. M. Moser, M. Czapiga, S. J. Siegel, C. M. Percopo, and H. F. Rosenberg. 2008. Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow. J. Immunol. 181: 4004-4009.
61. Jaffe, J. S., M. C. Glaum, D. G. Raible, T. J. Post, E. Dimitry, D. Govindarao, Y. Wang, and E. S. Schulman. 1995. Human lung mast cell IL-5 gene and protein expression: temporal analysis of upregulation following IgE-mediated activation. Am. J. Respir. Cell Mol. Biol. 13: 665-675.
62. McDermott, J. R., N. E. Humphreys, S. P. Forman, D. D. Donaldson, R. K. Grencis. 2005. Intraepithelial NK cell-derived IL-13 induces intestinal pathology associated with nematode infection. J. Immunol. 175: 3207-3213.
63. Heller, F., I. J. Fuss, E. E. Nieuwenhuis, R. S. Blumberg, and W. Strober. 2002. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17: 629-638.
64. Gibbs, B. F. 2005. Human basophils as effectors and immunomodulators of allergic inflammation and innate immunity. Clin. Exp. Med. 5: 43-49.
65. Wright, P. F., R. A. Karron, R. B. Belshe, J. R. Shi, V. B. Randolph, P. L. Collins, A. F. O'Shea, W. C. Gruber, and B. R. Murphy. 2007. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25: 7372-7378.
66. Cyr, S. L., T. Jones, I. Stoica-Popescu, D. Burt, and B. J. Ward. 2007. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine. Vaccine 25: 3228-3332.
67. Cyr, S. L., T. Jones, I. Stoica-Popescu, A. Brewer, S. Chabot, M. Lussier, D. Burt, and B. J. Ward. 2007. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine 25: 5378-5389.